secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001193125-26-008631
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Heron Therapeutics preliminary Q4 2025 net revenue $40.5M; full-year $154.9M
----------------------------------------------------------------------------

- Q4 2025 net revenue approximately $40.5M, driven by Acute Care franchise momentum.
- Full-year 2025 net revenue approximately $154.9M (preliminary, unaudited).
- ZYNRELEF net revenue $12.5M in Q4, up ~35% vs Q3 2025, largest product growth.
- APONVIE net revenue $3.8M, CINVANTI $22.9M, SUSTOL $1.3M in Q4 2025.
- CEO Craig Collard cites continued progress across all aspects of business.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/0001193125-26-008631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526008631/hrtx-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-008631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer